重组人血小板生成素治疗肺癌患者同步放疗、化疗后血小板减少的临床观察

Clinical observation on recombinant human thrombopoietin for treatment of concurrent chemoradiation-induced thrombocytopenia in lung cancer patients

目的:探讨重组人血小板生成素(Recombinant human thrombopoietin,rhTPO)治疗肺癌患者同步放疗、化疗后血小板(Blood platelet,PLT)减少的临床疗效和安全性。方法:接受同步放疗、化疗后PLTⅢ、Ⅳ度减少(PLT<50×109/L)的肺癌患者40例,随机分为治疗组(rhTPO)和对照组(IL-11),观察治疗疗效及不良反应。结果:治疗组PLT计数<50×109/L的天数比对照组缩短约2.4 d,PLT计数恢复至100×109/L以上所需时间平均缩短3.3 d,PLT计数恢复的最高值比对照组平均升高69×109/L以上。治疗组无需输注PLT,且不良反应少。结论:rhTPO能有效地缩短肺癌患者同步放疗、化疗后血小板减少持续时间,促进血小板恢复,安全性好。

Objective To evaluate the efficacy and safety of recombinant human thrombopoietin（rhTPO） in the treatment of concurrent chemoradiation-induced thrombocytopenia with lung cancer.Methods Forty patients with PLT 〈 50 x 109/L after concurrent chemoradiation were randomly divided into treatment group（received subcutaneous injection rhTPO） and control group（received subcutaneous injection IL-11）. The efficacy and adverse effects were observed.Results It was found that the time of PLT count 〈 50 x 109/L and PLT count recoverd to more than 100 x 109/L of treatment group were shorter.PLT count of treatment group was increased about 69 x 109/L than control group.The treatment group didn＇ t needed PLT infusion,and side effects were fewer.Conclusion rhTPO is capable of reducing the duration of thrombocytopenia and promoting PLT recovery.It has the high safety.